Navigation Links
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Date:9/8/2010

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions.

About N6022 N6022 is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. The initial Phase 1 testing in healthy subjects is designed to evaluate the safety, tolerability and pharmacokinetics of single, increasing intravenous dosages of N6022.  Data from this first-in-man trial will provide important safety, pharmacokinetic, and biomarker information on which to base the design of subsequent trials of N6022 as well as the development of reductase dosage forms suitable for chronic administration.

Targeting GSNORGSNOR breaks down s-nitrosoglutahione (GSNO), reducing the body's pool of GSNO.  In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects.   Similarly, in the gut GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR upregulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy.  GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNORN30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, a s-nitrosothi
'/>"/>

SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
2. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
3. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
4. Abbott Completes Acquisition of Piramals Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Supreme Court of Israel Rules in Favor of Sun Pharma
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Pharmacy Franchise Owners Association Taps David Mayper as Executive Director
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
11. Reportlinker Adds US Pharmaceutical Packaging Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... YORK , May 28, 2015 /PRNewswire/ ... developing new drugs and tests, and this ... the instruments that can assist them. This according ... publisher. Kalorama Information said instruments such as mass ... assist in the identification of drug targets ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ... Officer James H. Mackaness is scheduled to present ... at 9:00 am PT in Los Angeles ... may be accessed on the Event Calendar of the Investors ... of the webcast will be available shortly after the conclusion ...
(Date:5/28/2015)... , May 28, 2015 ... the addition of the "United States Medical ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in the United States ... Medical device manufacturers across the ...
Breaking Medicine Technology:Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3
... -- The,first of two stages of the ... Kamada's Alpha-1 Antitrypsin (AAT) liquid drug,candidate for ... the treatment of patients suffering from AAT,deficiency. ... profiles,and patient tolerability, leading the way to ...
... WIRE)--Jun 1, 2007 - Arrowhead Research,Corporation (Nasdaq:ARWR) ... been published in the 2007 American Society ... The data are from,an ongoing Phase I ... and pharmacokinetics of its lead anti-cancer drug,candidate, ...
Cached Medicine Technology:PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 2PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 3Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 2Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 3
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... OncLive proudly announces the 2015 Giants of ... a panel of eminent oncologists for landmark achievements that ... be introduced and celebrated TONIGHT at the 3rd Annual ... CDT at The Chicago Illuminating Company, 2110 S. Wabash ... groundbreaking accomplishments, in fields including translational research, gene therapy, ...
(Date:5/29/2015)... 2015 The report “Muscle Spasm ... on the therapeutic development for Muscle Spasm. Spasms ... the body, leading to many different symptoms and ... new targets and MOAs to produce first-in-class and ... review of Axillary Hyperhidrosis with 19 market data ...
(Date:5/29/2015)... AL (PRWEB) May 29, 2015 ... Fibromyalgia and Chronic Fatigue Syndrome is now offering ... Callers can learn about natural ways to reduce ... low moods, poor sleep, and brain fog. ... weekly Treating and Beating Fibromyalgia call in teleconferences ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... , March 16 MEDNET (MEDNETWorld.com), the ... Health Information Exchange (HIE) solutions, and Hielix, a leader ... healthcare information, today announced the State of North ... complete strategic operational and technical plans for the launch ...
... New chemotherapy agents appear associated with improvements in survival ... substantial cost, according to a report in the March ... one of the JAMA/Archives journals. David H. Howard, ... cancer registry database to measure trends in life expectancy ...
... March 16, 2010 A radiation therapy that uses ... to eliminate the primary tumor and ultimately may improve survival ... UT Southwestern Medical Center physicians who led a national clinical ... the March 17 issue of The Journal of the ...
... News media, scientists and others interested in finance, ... an American Chemical Society (ACS) Small & Medium Business ... you with subject matter experts and global thought leaders ... topics of interest to scientific and engineering professionals. ...
... Fastrack ... Internet based Hosting Solution for HME, Respiratory, Home Infusion Pharmacies and Home Healthcare Agencies. ... Plainview, NY ... for provider’s to convert to their Internet based Hosting Solution for ...
... ... P. Rogers is pleased to present their collection of handmade platform ... living. The nature of a platform bed demands precision in both ... this collection is no exception. Each bed is hand crafted using ...
Cached Medicine News:Health News:MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans 2Health News:MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans 3Health News:Precision radiation therapy may improve survival rates of some lung cancer patients 2Health News:A New Twist On Convert to Purchase 2Health News:Charles P. Rogers Shows Off Their New Platform Bed Collection 2Health News:Charles P. Rogers Shows Off Their New Platform Bed Collection 3Health News:Charles P. Rogers Shows Off Their New Platform Bed Collection 4
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Medicine Products: